Imaging software developer Median Technologies said it has secured a deal to manage medical images in two phase II clinical trials for hepatocelluar carcinoma.
The trials, which are sponsored by a global biopharmaceutical company, will involve acquisition of imaging data at 55 clinical sites in five Asian and five European countries, according to Median. Total patient enrollment will be 210 patients for the trials, which are expected to begin in early 2015.
Median said it would provide imaging services for the first study, enabling imaging data collection and quality control. In the second study, Median will also provide independent review services by radiologists using its LMS platform.
The company said it expects to receive 410,000 euros for its participation in the two projects.
